Takeda Pharmaceuticals reached settlement agreements with two Nevada plaintiffs who say the company’s Type 2 diabetes drug Actos gave them bladder cancer.
After more than a month of arguments and testimonies, the Japanese drugmaker reached confidential settlements with the two plaintiffs and stopped the jury trial. Earlier this month, Takeda also announced that more than 97 percent of plaintiffs opted into its multi-billion-dollar settlement plan, increasing Takeda’s original offer of $2.37 billion to $2.4 billion, Law 360 reported.
Legal experts say that Takeda is motivated to close down the Actos bladder cancer litigation and keep making settlements.
